DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia

ConclusionOur study suggested thatDOK6 promoter hypermethylation was a common molecular event in de novo AML patients. Remarkably,DOK6 promoter methylation could serve as an independent and integrated prognostic biomarker not only in non ‐APL AML patients but also in AML patients who are less than 60 years old.

Source: Cancer Medicine - October 16, 2019 Category: Cancer & Oncology Authors: Guo ‐Kang Sun, Li‐Juan Tang, Jing‐Dong Zhou, Zi‐Jun Xu, Lan Yang, Qian Yuan, Ji‐Chun Ma, Xing‐Hui Liu, Jiang Lin, Jun Qian, Dong‐Ming Yao Tags: ORIGINAL RESEARCH Source Type: research